Journal of Cancer Research and Clinical Oncology

, Volume 128, Issue 11, pp 610–616

Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases

  • Violetta Barbashina
  • Joseph Benevenia
  • Hana Aviv
  • James Tsai
  • Francis Patterson
  • Seena Aisner
  • Stanley Cohen
  • Helen Fernandes
  • Joan Skurnick
  • Meera Hameed
Original Paper

DOI: 10.1007/s00432-002-0389-3

Cite this article as:
Barbashina, V., Benevenia, J., Aviv, H. et al. J Cancer Res Clin Oncol (2002) 128: 610. doi:10.1007/s00432-002-0389-3

Abstract

Purpose. The objective of this study was to evaluate synovial sarcomas for the expression of oncogenic proteins (Her2/neu, EGFR, Bcl-2, p53) and proliferation markers (Ki-67, Topoisomerase 2α), as possible markers of prognostic significance.

Methods. From 17 patients with synovial sarcomas 19 tumors (15 primary, 2 recurrent, and 2 metastatic) were selected on the basis of characteristic histology, the expression of at least one epithelial marker, and/or the presence of t(X;18). Adequate follow-up was available in all cases.

Results. The tumors were tested immunohistochemically and were found to express multiple oncogenic proteins. Four of 19 synovial sarcomas (21%) demonstrated nuclear over-expression of p53 protein; 18 of 19 tumors (94%) stained positive for Bcl-2; and 13 of 19 tumors (68%) were immunoreactive with EGFR. Of particular interest was the frequent expression of Her2/neu, an oncogenic protein more commonly observed in epithelial neoplasms. Ten of 19 tumors (52%, 7 monophasic and 3 biphasic) showed positive cytoplasmic and membranous staining with Her2/neu (HercepTest, DAKO). The staining intensity ranged from 1+ to 2+. Cellular expression of Her2/neu was independent of EGFR positivity and showed no association with proliferative activity of the tumors. FISH analysis of eight positive cases showed no evidence of Her2/neu gene amplification. Among the non-metastatic tumors, we found a significant correlation between Ki-67 and Topoisomerase 2α. Spearman's correlation co-efficient was 0.86 with P=0.001 (n=17).

Conclusions. In this relatively small series of cases, we found no definite correlation between the over-expression of Her2/neu and clinical outcome. The over-expression of p53 was significantly associated with clinical outcome (Fisher's exact test, P=0.02).

Synovial sarcoma Oncogenes Her2/neu p53 Proliferation markers

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  • Violetta Barbashina
    • 1
  • Joseph Benevenia
    • 2
  • Hana Aviv
    • 4
  • James Tsai
    • 4
  • Francis Patterson
    • 2
  • Seena Aisner
    • 1
  • Stanley Cohen
    • 1
  • Helen Fernandes
    • 1
  • Joan Skurnick
    • 3
  • Meera Hameed
    • 1
  1. 1.Department of Pathology, UMDNJ-New Jersey Medical School, 185 South Orange Ave., Newark, N.J., USA
  2. 2.Department of Orthopedics, UMDNJ-New Jersey Medical School, Newark, N.J., USA
  3. 3.Department of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA
  4. 4.Department of Cytogenetics, UMDNJ-New Jersey Medical School, Newark, N.J., USA
  5. 5.Division of Hematology & Oncology, Department of Medicine, Brown University School of Medicine, Providence, Rhode Island, USA